

Title (en)
COMBINATION PREPARATION, PARTICULARLY FOR TREATING PROSTATE CANCER

Title (de)
KOMBINATIONSPRÄPARAT INSBESONDERE ZUR THERAPIE DES PROSTATAKARZINOMS

Title (fr)
PREPARATION COMBINEE, EN PARTICULIER POUR TRAITER LE CANCER DE LA PROSTATE

Publication
EP 1904018 A2 20080402 (DE)

Application
EP 06762663 A 20060717

Priority
• EP 2006007027 W 20060717
• EP 05015692 A 20050719
• EP 06762663 A 20060717

Abstract (en)
[origin: EP1745796A1] Composition (A) comprising an inhibitor (I) of 5alpha -reductase; an estrogen receptor beta -agonist (II) and an inhibitor (III) of prostate-specific antigen (PSA), for simultaneous or sequential administration, is new. ACTIVITY : Cytostatic. Results for the effects of individual components on the growth of prostatic cancer cells are given but no results for the combination of (I)-(III). MECHANISM OF ACTION : Inhibition of 5alpha -reductase and PSA, and agonism of the estrogen receptor, resulting in reduced bioavailability of insulin-like growth factor -1 (which has a proliferation-stimulating effect) and reduced secretion of vascular endothelial growth factor (so inhibiting formation of new blood vessels).

IPC 8 full level
A61K 6/00 (2006.01)

CPC (source: EP)
A23L 33/105 (2016.07); **A61K 36/28** (2013.01); **A61K 36/71** (2013.01); **A61K 36/85** (2013.01); **A61K 36/896** (2013.01); **A61P 35/00** (2017.12); **A23V 2002/00** (2013.01)

C-Set (source: EP)
A23V 2002/00 + **A23V 2200/308** + **A23V 2250/21**

Citation (search report)
See references of WO 2007009734A2

Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DOCDB simple family (publication)
EP 1745796 A1 20070124; EP 1904018 A2 20080402; WO 2007009734 A2 20070125; WO 2007009734 A3 20070419

DOCDB simple family (application)
EP 05015692 A 20050719; EP 06762663 A 20060717; EP 2006007027 W 20060717